BNO 5.26% 20.0¢ bionomics limited

Ann: BNC105 Clinical Trial In Combination With Nivolumab, page-10

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 593 Posts.
    lightbulb Created with Sketch. 24

    I don't want to speculate about the possibility of BNC105 as a combo producing a positive trial outcome. But, I reiterate that it is worth a shot as a combo treatment. Plenty of success stories with combo treatments. However, I also have to agree that it is secondary to the the forthcoming outcome of the "agitation" trial. There is quite a bit riding on that trial. GLTA


 
watchlist Created with Sketch. Add BNO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.